日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中,对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

纳武利尤单抗联合伊匹木单抗和化疗作为转移性非小细胞肺癌患者一线治疗方案:CheckMate 9LA 研究的最终 6 年结果

Carbone, D P; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Felip, E; Cheng, Y; Juan-Vidal, O; Alexandru, A; Mizutani, H; Reinmuth, N; Lu, S; Reck, M; John, T; Scherpereel, A; De Marchi, P; Aoyama, T; Sathyanarayana, P; Grootendorst, D J; Hu, N; Ip, V; Hung, Y-H; Paz-Ares, L G

Discussing Human and Environmental Health Co-Benefits Related to Diet and Mobility Behaviours in the Primary Care Setting: A Qualitative Exploratory Study

在初级保健机构中探讨与饮食和出行行为相关的人类和环境健康协同效益:一项定性探索性研究

Sigrist, Aline; Richardet, Elodie; Senn, Nicolas; Schwarz, Joëlle

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

CheckMate 9LA随机试验中,一线纳武利尤单抗联合伊匹木单抗和化疗治疗转移性非小细胞肺癌的四年临床更新和治疗转换调整后的结果

Carbone, David P; Ciuleanu, Tudor-Eliade; Schenker, Michael; Cobo, Manuel; Bordenave, Stéphanie; Juan-Vidal, Oscar; Menezes, Juliana; Reinmuth, Niels; Richardet, Eduardo; Cheng, Ying; Mizutani, Hideaki; Felip, Enriqueta; Zurawski, Bogdan; Alexandru, Aurelia; Paz-Ares, Luis; Lu, Shun; John, Thomas; Zhang, Xiaoqing; Mahmood, Javed; Hu, Nan; De, Tuli; Santi, Irene; Penrod, John R; Yuan, Yong; Lee, Adam; Reck, Martin

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

一项随机、开放标签的 II 期研究,旨在评估纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗高肿瘤突变负荷的晚期或转移性实体瘤患者的疗效。

Schenker, Michael; Burotto, Mauricio; Richardet, Martin; Ciuleanu, Tudor-Eliade; Gonçalves, Anthony; Steeghs, Neeltje; Schoffski, Patrick; Ascierto, Paolo A; Maio, Michele; Lugowska, Iwona; Lupinacci, Lorena; Leary, Alexandra; Delord, Jean-Pierre; Grasselli, Julieta; Tan, David S P; Friedmann, Jennifer; Vuky, Jacqueline; Tschaika, Marina; Konduru, Somasekhar; Vemula, Sai Vikram; Slepetis, Ruta; Kollia, Georgia; Pacius, Misena; Duong, Quyen; Huang, Ning; Doshi, Parul; Baden, Jonathan; Di Nicola, Massimo

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

纳武利尤单抗联合卡博替尼对比舒尼替尼一线治疗晚期肾细胞癌:来自 III 期随机 CheckMate 9ER 试验的延长随访结果

Powles, T; Burotto, M; Escudier, B; Apolo, A B; Bourlon, M T; Shah, A Y; Suárez, C; Porta, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; George, S; Scheffold, C; Wang, P; Fedorov, V; Motzer, R J; Choueiri, T K

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

在 ARAMIS 研究中,达罗鲁胺治疗非转移性去势抵抗性前列腺癌的长期安全性和耐受性以及不良事件发生时间进程

Shore, Neal D; Gratzke, Christian; Feyerabend, Susan; Werbrouck, Patrick; Carles, Joan; Vjaters, Egils; Tammela, Teuvo L J; Morris, David; Aragon-Ching, Jeanny B; Concepcion, Raoul S; Emmenegger, Urban; Fleshner, Neil; Grabbert, Markus; Lietuvietis, Vilnis; Mahammedi, Hakim; Cruz, Felipe M; Paula, Adriano; Pieczonka, Christopher; Rannikko, Antti; Richardet, Martin; Silveira, Glauco; Kuss, Iris; Le Berre, Marie-Aude; Verholen, Frank; Sarapohja, Toni; Smith, Matthew R; Fizazi, Karim

HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America

HOLA COVID-19 研究:评估护理 COVID-19 患者对拉丁美洲癌症治疗服务的影响

Bernabe-Ramirez, Carolina; Velazquez, Ana I; Olazagasti, Coral; Decat Bergerot, Cristiane; Bergerot, Paulo Gustavo; Corona Cruz, Jose; Riano, Ivy; Adaniel, Christina; Ramirez, Francisca; Anampa, Jesus; Cajina, Carmen; Mena, Evelin; Gracia, Elias; Menendez, Alvaro; Idrovo, Henry; Bezares, Raimundo; Castillo Fernandez, Omar Orlando; Duque, Liseth; Corrales-Rodríguez, Luis; Ramos, Glenda; Kihn-Alarcón, Alba J; Schlam, Ilana; Bruno, Ximena; Umanzor, Gerardo; Castro, Jenny Lissette; Losco, Federico; Ubillos, Luis; Richardet, Eduardo; Soto-Perez-de-Celis, Enrique; Duma, Narjust

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

纳武利尤单抗联合卡博替尼对比舒尼替尼治疗晚期肾细胞癌

Choueiri, Toni K; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Zurawski, Bogdan; Oyervides Juárez, Victor M; Hsieh, James J; Basso, Umberto; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Goh, Jeffrey C; Barrios, Carlos; Richardet, Martin; Porta, Camillo; Kowalyszyn, Rubén; Feregrino, Juan P; Żołnierek, Jakub; Pook, David; Kessler, Elizabeth R; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang, Joshua; Maurer, Matthew A; Simsek, Burcin; Ejzykowicz, Flavia; Schwab, Gisela M; Apolo, Andrea B; Motzer, Robert J

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

一线治疗晚期非小细胞肺癌,比较纳武利尤单抗联合伊匹木单抗加两周期化疗与单纯化疗(四周期)的疗效:CheckMate 9LA 两年更新研究

Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, T